Akums, a leading player in pharmaceutical manufacturing, and The Government of The Republic of Zambia (GRZ), have announced a partnership to set up a manufacturing facility in Zambia to provide high quality and affordable generic medicines for patients in Zambia.The partnership will involve setting up a state-of-the-art manufacturing facility in Zambia to manufacture and supply medicines in Zambia. The JV also, in the future, will export to neighboring African countries like Zimbabwe, Namibia, Botswana, Malawi, Tanzania, Mozambique etc.The manufacturing facility will be housed in a newly formed Joint venture company (JV), which will be headquartered in Zambia. Akums will hold 51% while GRZ, though its nominated state instrumentality, will hold 49% in this joint venture. The JV will be managed by a Board with representatives from both partners. The JV is expected to be established by Q3 FY 26, post which the construction of facility will begin.Commercial supplies from the facility are expected to begin in Q3 FY 28, subject to timely establishment of the facility and regulatory approvals for the facility and products. The facility will manufacture tablets, hard gelatin capsules, liquids, injectables as well as beta-lactam products. Both partners will contribute in the establishment and operationalization of the facility in ratio of their shareholding.To fulfill the current national healthcare needs, the Govt. of Zambia has also committed to purchase essential medicines from Akums' facilities in India to Zambia. The supply will be of minimum USD 25 million annually in calendar years 2026 and 2027.Zambia is one of the fastest growing economies in Africa with GDP growth being expected at over 6% in 2025. Zambia's pharma market is projected to expand by over 10%+ annually over the next 5 years and surpass USD 300 million by 2030. Currently over 75% of Zambia's essential medicines are imported and this partnership will allow the country to move towards self-reliance in healthcare and reduce import dependency. Additionally, the partnership holds export potential to other African nations, particularly SADC countries, with a combined population of over 450 million and a fast-growing pharmaceutical market."We are proud to partner with GRZ to deliver high quality, affordable medicines manufacturing for Zambian healthcare system. This is our first manufacturing partnership outside India and aligns with vision of becoming a global CMDO," said Mr. Sanjeev Jain, Managing Director at Akums.About AkumsAkums Drugs and Pharmaceuticals Limited, is the largest India-focused contract development and manufacturing organization (CDMO). It has 11 manufacturing facilities in India for its CDMO formulation business and two manufacturing units for its API manufacturing business. Akums manufactures over 4,000 formulations across 60+ dosage forms. It has 4 state-of-the-art R&D centers, with over 1,000 DCGI approvals and 250+ first time in India approvals. Akums and The Govt of The Republic of Zambia Announce Joint Venture to Establish Pharmaceutical Manufacturing Facility in Zambia

Akums Drugs and Pharmaceuticals Ltd., India's largest contract development and manufacturing organization (CDMO), has announced its consolidated financial results for the quarter ended June 30, 2025. This quarter continued to display strong performance with healthy growth in Adj EBITDA and Adj PAT.In Q1 FY26, Akums reported total income of Rs. 1,051 crore, with healthy Adj EBITDA of Rs. 156 crore reflecting a robust 19.1% year-on-year (YoY) growth. The margins improved to 14.8% from 12.7% last year a 208 bps improvement.During this quarter, the company achieved a key milestone of reaching 1,000 Drug Controller General of India (DCGI) approvals, with 27 fresh approvals in this quarter. The DCGI approvals assist the company in enhancing its product mix, building a differentiated and research-driven portfolio. Additionally, the company also received a patent for its extended-release combination formulation of Doxylamine and Pyridoxine developed using the company's tablet in tablet technology.As part of Akums' strategic vision to establish itself as a leading global CDMO, the company received its first EU dossier approval for Rivaroxaban. It also filed its first dossier of Dapagliflozin combination in Switzerland. Both of these new products hold significant market potential. The commercialization of the EU contract also continues to be on track and the company will commence commercial supplies from April 2027.Akums received 100 mn Euros as part consideration for the EU contract in Q1 this year, consequently the company is at a cash surplus of Rs. 1,518 cr. The strong liquidity position provides a robust foundation for Akums to strategically scale up its business operations through both organic growth initiatives and inorganic opportunities.Segmental Performance Overview Akums' flagship business, CDMO, contributed ~79% to the group turnover with an EBITDA of 14.7% in Q1 FY 26. The company's domestic branded formulation business segment reported ~3% YoY growth while international branded formulation business grew by ~2% YoY. Trade generics and API segment continue to be in operational loss this quarter, though, through the management efforts, the losses are gradually reducing.Commenting on the results, Mr. Sanjeev Jain, Managing Director, said, "This date marks just over one year since we got listed. We continue to work towards strengthening the organization with a focus on long term growth. Our commitment to becoming a global CDMO player remains steadfast. The recent filings along with the planned global approvals of other facilities are setting up us in that endeavor."Mr. Sandeep Jain, Managing Director, added, "We continue to deliver strong performance despite the industry headwinds of decreasing API prices and muted volume growth. With a sustained focus on R&D, we have been able to deliver robust growth. Achieving 1,000 DCGI approvals is a key milestone that stands out Akums from its peers, allowing Akums to offer margin accretive differentiated offerings. We remain focused on strengthening our CDMO leadership, scaling high-value capabilities, and driving operational excellence. Backed by a strong pipeline and prudent capital allocation, we are well-positioned to deliver sustainable and profitable growth in the years ahead."Extract of Consolidated financial resultsParticulars (Rs Cr)Q1 FY 26Q4 FY 25Q1 FY 25 Revenue 1,024 1,056 1,019 Other income 27 18 7Total income1,0511,0731,026 Cost of goods sold 582 639 596 Employee Cost 176 184 176 Other Expenses 137 139 123Adj EBITDA156111131Adj EBITDA Margin14.8%10.4%12.7%Adj PAT654457Adj PAT Margin6.2%4.1%5.6%Definitions Adjusted EBITDA has been calculated as the sum of profit/ (loss) for the quarter, tax expenses, finance costs, depreciation and amortization expense, fair value changes to financial instruments, and exceptional items.Adjusted PAT is calculated as the profit for the quarter plus fair value changes to financial instruments less tax deferred tax created on brought forward losses.CDMO: Contract Development and Manufacturing OperationsAPI: Active Pharmaceutical Ingredients Akums Reports Q1 FY26 with 19% YoY Adj EBITDA Growth; Achieves 1,000 DCGI Approvals

Akums Drugs and Pharmaceuticals Ltd., India's largest contract development and manufacturing organization (CDMO), has announced its consolidated financial results for the quarter and fiscal year ending March 31, 2025. The fourth quarter marked a significant rebound in performance, laying a strong foundation for continued growth and global expansion.In Q4 FY25, Akums reported revenue of Rs.1,073 crore, reflecting a robust 12.4% year-on-year (YoY) growth. The company posted a 10.4% EBITDA margin. Building on its Q4 momentum, Akums closed FY25 with consolidated total income of Rs. 4,170 crore and an adjusted EBITDA margin of 12.3%, a 7-basis point improvement from the previous year. The company continued its focus on enhancing its product mix, building a differentiated, research-driven portfolio, and expanding its global presence.One of the key developments during the fiscal year was securing an approx. €200 million contract for the manufacture and supply of pharmaceutical products to regulated European markets - a milestone that significantly expands Akums' global CDMO footprint. The commercial supplies for this will begin in 2027. To support its expanding footprint, Akums invested Rs. 272 crore in capital expenditure during FY25. which now stands at 49.6 billion units annually. This infrastructure scale-up ensures readiness for large-scale domestic CDMO operations as well as global pharma opportunities.Akums also maintained a strong R&D focus, investing Rs. 130 crore which is over 3% of revenue. With 973 DCGI approvals now, the company's product portfolio has over 4,000 commercialized formulations. This is across multiple therapeutic areas across 60+ dosage forms.Segmental Performance OverviewAkums' flagship business, CDMO, contributed ~78% to the group turnover with an adjusted EBITDA of 14.1% in FY 25. The company's domestic branded formulation business segment reported ~9% growth while international branded formulation business grew by ~14%. Trade generics and API segment continue to be in operational loss this fiscal, but the company is taking firm measures to cut the losses in the coming fiscal.Strategic Focus and Future OutlookDespite making meaningful progress across key business segments, Akums reported flat year-on-year revenue, largely due to muted industry volumes and price erosion in APIs. The company, however, continued to invest in long-term growth drivers to consolidate its leadership position in India's pharmaceutical landscape and lay the foundation for global CDMO expansion.With an R&D spend, up 16% from FY24, Akums continues to deepen its innovation capabilities, develop complex formulations, and enrich its portfolio. The company's emphasis on quality-focused manufacturing, novel delivery formats, and patient-centric innovations ensures that its offerings are both globally relevant and therapeutically effective.Commenting on the results, Mr. Sanjeev Jain, Managing Director, said, " As we look back on the year we got listed, we also look ahead with a renewed sense of purpose. Our entry into Europe is a pivotal step for the Akums' global CDMO expansion. Coupled with strategic capacity expansion and a sharp focus on differentiated offerings, we are laying the foundation for Akums to emerge as a trusted global CDMO. We remain steadfast in our commitment to creating long-term value for all stakeholders and to delivering healthcare solutions that impact lives across geographies."Mr. Sandeep Jain, Managing Director, added, "It gives us immense pride to close FY25 on a positive note, especially in a year marked by volatility across the pharmaceutical industry. Despite price erosion in APIs and slowing volumes, Akums remained focused on the fundamentals-operational discipline, innovation, and global ambition. Our new injectable facility is now operational, our R&D engine is stronger than ever, and our differentiated portfolio continues to resonate with partners. These are exciting times, as we accelerate our transformation into a global pharmaceutical manufacturing organization."Here is the Summary of Profit and Loss Statement for referenceP/L (Rs Cr)Q4 FY 25Q3 FY 25Q4 FY 24FY 25FY 24Revenue1,0561,0109444,1184,178Other Income1815105234Total income1,0731,0259544,1704,212COGS6396025692,4332,550Employee Cost184176164716647Other Expenses139111128508500Adj EBITDA11113698513515Adj EBITDA Margin10.4%13.3%10.3%12.3%12.2%Depreciation404534153126Finance Cost55123551Exceptional Item-8-50-1726Adj PAT446646234220Adj PAT Margin4.1%6.5%4.8%5.6%5.2% Akums Reports Q4 FY25 with 12.4% Revenue Growth, FY25 Adj. EBITDA Remained Strong at 12.3%

Delhi, India--(Newsfile Corp. - August 21, 2025) - Akums Drugs & Pharmaceuticals Ltd., India's largest contract development and manufacturing organization (CDMO), proudly announces that its Sterile Manufacturing Plant has been granted the prestigious Good Manufacturing Practices (GMP) certification by ANVISA, the Brazilian Health Regulatory Agency. This certification is a significant global milestone, enabling Akums to enhance its footprint in Brazil and other regulated markets across Latin...

New Delhi: Akums Drugs and Pharmaceuticals Limited has received European Good Manufacturing Practice (EU-GMP) certificates for its two manufacturing facilities, Plant 1 and Plant 2, both located at...

New Delhi: The National Pharmaceutical Pricing Authority (NPPA) has fixed the retail price of Cetirizine Hydrochloride IP eq. to Cetirizine 0.24 % w/v plus Benzalkonium Chloride Solution IP 0.02 %...

Bafna joined Akums Drugs as finance president on August 8, 2025.

New Delhi: The Subject Expert Committee (SEC) under the Central Drugs Standard Control Organisation (CDSCO) has recommended granting permission to Akums Healthcare for the manufacture and marketing...

New Delhi: The Subject Expert Committee (SEC), functioning under the Central Drugs Standard Control Organisation (CDSCO), has recommended granting permission to Akums Drugs and Pharmaceuticals to...

New Delhi: In a significant step towards advancing research and development in pharmaceutical formulations, Akums Drugs and Pharmaceuticals has entered into a Memorandum of Agreement (MoA) with...

The Delhi Airport informed that "flight operations are currently being conducted under CAT III conditions due to dense fog, which may result in delays or cancellations."

Waves of toxic smog have only increased in the national capital over the past few weeks with the air quality index staying in the 'hazardous' category.

Akums Drugs & Pharmaceuticals Ltd., Titagarh Rail Systems Ltd., ICICI Bank Ltd., Hindalco Industries Ltd., Hyundai Motor India Ltd., and HCL Tech are among the companies garnering brokerage commentary

Akums Wins 20-Year Patent for Dual Release PPI, Promises Long-Lasting GERD Relief  Medical Dialogues

Akums Secures Patent for Innovative GERD Treatment  TipRanks

Akums secures patent for dual-action nausea drug for pregnant women  Business Standard

Live Events as a Reliable and Trusted News Source Addas a Reliable and Trusted News Source Add Now! (You can now subscribe to our (You can now subscribe to our Economic Times WhatsApp channel Citing Delhi’s worsening air pollution as...